DigestRedComo funciona
Red
/
Empresas
Vi
No verificado

ViiV Healthcare

Sobre qué escribimos

FarmacéuticaIndustriaMedicina - VariosSaludVIH, SIDA y enfermedades autoinmunes

26 Comunicados de prensa

Ver todos los comunicados de prensa
04/08/2026
ViiV Healthcare Launches “Do It For Future You” Campaign Inspiring People to Prioritize Their Sexual Health and Future
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
29/07/2026
Eventos
VIH, SIDA y enfermedades autoinmunes
Salud
Medicina - Varios
Ciencia
Farmacéutica
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
27/07/2026
Eventos
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
21/07/2026
Eventos
Industria
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Salud
Farmacéutica
Sanidad
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
01/06/2026
PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
10/04/2026
Industria
Biotecnología
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Jóvenes
Salud
Ir de compras
The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
25/02/2026
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
25/02/2026
Eventos
Ferias y Congresos
Industria
VIH, SIDA y enfermedades autoinmunes
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
18/02/2026
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Biotecnología
Sanidad
Farmacéutica
Salud
Industria
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0
17/02/2026
Eventos
Industria
Ciencia
Biotecnología
Farmacéutica
VIH, SIDA y enfermedades autoinmunes
Salud
Medicina - Varios
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
Fuente
ViiV Healthcare
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0